2012-06-12-世界卫生组织-Hepatitis_A_Vaccine_Information_sheet_4页_209kb

Key Points on Hepatitis A Vaccine Observations

The report details the observed rates of vaccine reactions for hepatitis A vaccines, emphasizing safety data from global sources.

Vaccine Types and Characteristics
Hepatitis A vaccines include monovalent (inactivated and live attenuated) and combination vaccines with other pathogens, such as hepatitis B or S. typhi. Inactivated vaccines use various strains and excipients, with antigen content expressed in ELISA units or similar. Live attenuated vaccines are under development but have limited data. Combination vaccines, like those with hepatitis B or S. typhi, share similar safety profiles with monovalent versions.

Mild Adverse Events
Common mild reactions include injection site soreness, induration, headache, malaise, and gastrointestinal symptoms. Rates vary by age and vaccine: soreness (14-27% in children, 43-56% in adults), induration (4%), headache (4-16%), and other symptoms occurring in less than 5% of cases. Most resolve within 48 hours.

Severe Adverse Events
No causal links have been established between hepatitis A vaccines and severe events like anaphylaxis, Guillain-Barré syndrome, or other serious conditions. Events reported post-licensure are not more frequent than background rates, indicating overall good safety.

Other Considerations
Safety in immunocompromised individuals (e.g., transplant recipients) is demonstrated, but pregnant use lacks data. Coadministration with other vaccines or specific combinations does not increase risks. The report is based on extensive studies but does not cover live attenuated vaccines in detail.

Conclusion
Hepatitis A vaccines are generally safe and immunogenic, with predominant mild side effects observed. No severe adverse events have been attributed causally to the vaccines. This summary aligns with WHO recommendations and safety assessments.